R. Cervera, J. Piette, J. Font, M. A. Khamashta, Y. Shoenfeld et al., Europhospholipid project group, antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a, Arthritis Rheum, vol.46, pp.1019-1027, 2002.

G. Finazzi, R. Marchioli, V. Brancaccio, P. Schinco, F. Wisloff et al., A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS), J. Thromb. Haemost, vol.3, pp.848-853, 2005.

M. A. Crowther, J. S. Ginsberg, J. Julian, J. Denburg, J. Hirsh et al., A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome, N. Engl. J. Med, vol.349, pp.1133-1138, 2003.

H. Cohen, B. J. Hunt, M. Efthymiou, D. R. Arachchillage, I. J. Mackie et al., Trial Investigators, Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, openlabel, phase 2/3, non-inferiority trial, Lancet Haematol, vol.3, pp.30079-30084, 2016.

C. Belizna, Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome, Autoimmun. Rev, vol.14, pp.358-362, 2015.

A. V. Kinev and R. A. Roubey, Tissue factor in the antiphospholipid syndrome, Lupus, vol.17, pp.952-958, 2008.

O. Amengual, T. Atsumi, M. A. Khamashta, and G. R. Hughes, The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome, Thromb. Haemost, vol.79, pp.276-281, 1998.

J. Kassis, C. Neville, J. Rauch, L. Busque, E. R. Chang et al., Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis, Thromb. Haemost, vol.92, pp.1312-1319, 2004.

M. Charakida, C. Besler, J. R. Batuca, S. Sangle, S. Marques et al., Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome, JAMA, vol.302, pp.1210-1217, 2009.

Y. Benhamou, J. Bellien, G. Armengol, E. Brakenhielm, S. Adriouch et al., Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome, Arthritis Rheumatol, vol.66, pp.3210-3220, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02296566

V. Proulle, R. A. Furie, G. Merrill-skoloff, B. C. Furie, and B. Furie, Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS, Blood, vol.124, pp.611-622, 2014.

W. Zhang, F. Gao, D. Lu, N. Sun, X. Yin et al., Anti-?2 glycoprotein I antibodies in complex with ?2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2? and glycoprotein I b?, Front. Med, vol.10, pp.76-84, 2016.

H. M. Spronk, J. W. Govers-riemslag, and H. Cate, The blood coagulation system as a molecular machine, BioEssays, vol.25, pp.1220-1228, 2003.

H. C. Hemker, R. Dieri, E. De, S. Smedt, and . Béguin, Thrombin generation, a function test of the haemostatic-thrombotic system, Thromb. Haemost, vol.96, pp.553-561, 2006.

S. Liestøl, P. M. Sandset, M. Mowinckel, and F. Wisløff, Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants, J. Thromb. Haemost, vol.5, pp.2204-2210, 2007.

S. Zuily, V. Regnault, F. Guillemin, P. Kaminsky, A. Rat et al., Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study, Thromb. Res, vol.132, pp.1-7, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01709884

M. Efthymiou, A. S. Lawrie, I. Mackie, D. Arachchillage, P. J. Lane et al., Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome, Thromb. Res, vol.135, pp.1191-1197, 2015.

A. Rousseau, P. Van-dreden, E. Mbemba, I. Elalamy, A. Larsen et al., Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin, Thromb. Res, vol.136, pp.1273-1279, 2015.

M. Sassi, T. Chakroun, E. Mbemba, P. Van-dreden, I. Elalamy et al., The antithrombotic potential of Tinzaparin and enoxaparin upon thrombin generation triggered in vitro by human ovarian Cancer cells IGROV1, Clin. Appl. Thromb. Off. J. Int. Acad. Clin. Appl. Thromb, vol.23, pp.155-163, 2017.

G. T. Gerotziafas, V. Galea, E. Mbemba, M. Sassi, M. Roman et al., Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3, Curr. Vasc. Pharmacol, vol.12, pp.893-902, 2014.

Y. Dargaud, A. S. Wolberg, R. Luddington, V. Regnault, H. Spronk et al., Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study, Thromb. Res, vol.130, pp.929-934, 2012.

J. Perrin, F. Depasse, and T. Lecompte, French-speaking CAT group and under the aegis of GEHT, French-speaking CAT group (all in France unless otherwise stated):, French-speaking CAT group all in France unless otherwise stated, Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma, Thromb. Res, vol.136, pp.125-130, 2015.

Y. Dargaud, R. Luddington, E. Gray, T. Lecompte, T. Siegemund et al., Standardisation of thrombin generation test-which reference plasma for TGT? An international multicentre study, Thromb. Res, vol.125, pp.353-356, 2010.

I. L. Geenen, M. J. Post, D. G. Molin, G. W. Schurink, J. G. Maessen et al., Coagulation on endothelial cells: the underexposed part of Virchow's triad, Thromb. Haemost, vol.108, pp.863-871, 2012.

S. Miyakis, M. D. Lockshin, T. Atsumi, D. W. Branch, R. L. Brey et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost, vol.4, pp.295-306, 2006.

G. Ruiz-irastorza, M. Crowther, W. Branch, and M. A. Khamashta, Antiphospholipid syndrome, Lancet Lond. Engl, vol.376, issue.10, p.60709, 2010.

J. H. Rand, X. X. Wu, A. S. Quinn, and D. J. Taatjes, Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome, Lupus, vol.17, pp.922-930, 2008.

S. S. Pierangeli, M. Colden-stanfield, X. Liu, J. H. Barker, G. L. Anderson et al., Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo, Circulation, vol.99, pp.1997-2002, 1999.

C. Mineo, Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis, Curr. Rheumatol. Rep, vol.15, 2013.

V. Regnault, S. Béguin, D. Wahl, E. De-maistre, H. Hemker et al., Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants, Thromb. Haemost, vol.89, pp.208-212, 2003.

R. Simantov, J. M. Lasala, S. K. Lo, A. E. Gharavi, L. R. Sammaritano et al., Activation of cultured vascular endothelial cells by antiphospholipid antibodies, J. Clin. Invest, vol.96, pp.2211-2219, 1995.